<DOC>
	<DOCNO>NCT00450619</DOCNO>
	<brief_summary>Background : - No treatment know improve survival prostate cancer patient help previous treatment hormone chemotherapy . - An experimental vaccine call prostate specific antigen ( PSA ) /TRICOM contain gene protein produce prostate cancer cell call prostate-specific antigen ( PSA ) . The vaccine trigger immune system make cell may able recognize attack cancer cell make PSA . - Granulocyte macrophage colony stimulate factor ( GM-CSF ) approve drug usually give increase patient 's white blood cell count stimulate immune system . - 1Samarium-153-ethylene diamine tetramethylene phosphonate ( 53Sm-EDTMP ) radioactive drug approve many year treat advanced prostate cancer . It give vein target directly tumor bone relieve pain cause bone lesion . Radiation also increase level certain protein inside tumor , make easy immune system find kill tumor cell . - When laboratory mice give vaccine , radiation , combination , combination effective treating tumor . Objectives : -To determine combine treatment PSA/TRICOM vaccine 153Sm-EDTMP radiation delay progression prostate cancer good radiation alone . Eligibility : -Patients advanced prostate cancer worsen despite treatment hormone , two bone lesion related prostate cancer , prior treatment docetaxel chemotherapy . Design : - Patients randomly assign receive radiation alone ( Arm A ) radiation vaccine sargramostim ( Arm B ) . - Arm A receive 153Sm-EDTMP radiation start study day 8 repeat every 12 week . - Arm B receive prim vaccine study day 1 radiation day 8 . Radiation therapy repeat every 12 week . Boosting vaccine give day 15 29 monthly . GM-CSF give vaccination ( day vaccination next 3 day ) enhance immune response . Vaccinations GM-CSF give injection skin , usually thigh . Radiation therapy give vein . - Patients monitor regularly physical examination , blood urine test , scan evaluate safety treatment response . - Patients human leukocyte antigen serotype within HLA-A A serotype group ( HLA-A2 ) -positive undergo apheresis , procedure similar donating blood , obtain immune cell call lymphocyte measure immune response vaccine .</brief_summary>
	<brief_title>153Sm-EDTMP With Without PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer</brief_title>
	<detailed_description>Background - There standard therapy option show prolong survival patient progressive disease first-line docetaxel-based regimen men metastatic castration resistant prostate cancer ( CRPC ) . - Ninety percent men population bone metastasis . - PSA/TRICOM vaccine single agent induce generation PSA-specific T cell majority patient objective response PSA decline minority patient . Furthermore , generation least 6-fold increase PSA-specific T cell significantly correlate evidence clinical benefit . - Radiation alter phenotype tumor cell ( increase Fas , increase major histocompatibility complex ( MHC ) , increase tumor-associated molecule increase ICAM ) , make much amenable immune-mediated killing . - ( 153 ) Sm EDTMP beta emitter ( gamma emission ) target osteoblastic bone lesion ( find prostate cancer ) . - ( 153 ) Sm EDTMP , Food And Drug Administration ( FDA ) -approved dos use clinically palliation prostate cancer , cause phenotypic change tumor cell , lead improve kill cell cytotoxic T-cell assay vitro . - The combination vaccine radiation greatly increase antitumor efficacy murine subcutaneous tumor model . Objectives - Primary-A comparison progression-free survival 4 month Arm A ( 153 ) Sm EDTMP alone ) Arm B ( 153Sm EDTMP vaccine ) . - Secondary-Objective response , PSA outcomes , immunologic response , toxicity , palliation overall survival . Eligibility - Patients metastatic CRPC 2 bone lesion consistent prostate cancer treat docetaxel-based regimen . - Patients symptomatic soft tissue disease parenchymal disease exclude . Design - Randomized phase 2.5 study . - Sixty-eight patient enrol randomize : - Arm A : ( 153 ) Sm-EDTMP : 1 mCi/kg intravenous ( IV ) one minute day 8 . ( 153 ) Sm-EDTMP repeat every 12 week adequate hematologic recovery . Arm B : PROSTAC-V/TRICOM ( vaccinia ) 2 x 10^8 plaque form unit ( pfu ) subcutaneously day 1 . - ( 153 ) Sm-EDTMP : 1 mCi/kg IV one minute day 8 . ( 153 ) Sm-EDTMP repeat every 12 week adequate hematologic recovery . PROSTVAC-F/TRICOM ( fowlpox ) 1 x 10^9 pfu subcutaneously day 15 , 29 , every 4 week .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Samarium ethylenediaminetetramethylenephosphonate</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>INCLUSION CRITERIA : A. Histopathological documentation prostate cancer confirm Laboratory Pathology National Institutes Health ( NIH ) Clinical Center , National Institutes Health ( NIH ) , National Naval Medical Center , Walter Reed Army Medical Center ; participate Institute 's Department Pathology prior start study . If pathologic specimen available , patient may enroll pathologist 's report show histologic diagnosis prostate cancer clinical course consistent disease . B . Must metastatic castration resistant prostate cancer ( CRPC ) least 2 bone lesion consistent prostate cancer metastasis progressive disease ( 2 rise PSA value separate least one week , new enlarge lesion consistent prostate cancer , clinical progression ) docetaxel metastatic prostate cancer inability tolerate docetaxel . C. Life expectancy great equal 6 month . D. Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . E. No systemic steroid steroid eye drop use within 2 week prior initiation experimental therapy . F. Hematological eligibility parameter ( within 16 day start therapy ) . Granulocyte count great equal 1,500/mm^3 Platelet ( PLT ) count great equal 100,000/mm^3 Hemoglobin ( Hgb ) great equal 10 Gm/dL ( Transfusion may give accomplish ) G. Biochemical eligibility parameter ( within 16 day start therapy ) Hepatic function : aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) less 2.5 time upper limit normal ; bilirubin le 1.5 mg/dL OR patient Gilbert 's syndrome , total bilirubin less equal 3.0 mg/dL . H. No active malignancy within past 12 month ( exception nonmelanoma skin cancer carcinoma situ bladder treat curative intent ) lifethreatening illness . I . Willing travel National Institutes Health ( NIH ) participate Institute followup visit . J . 18 year age great . K. Able understand sign inform consent . L. Agree use adequate contraception prior study entry least 4 month follow last vaccine injection . M. Patients must remain medical castration therapy testosteronesuppressing therapy ( e.g. , gonadotropin release hormone ( GnRH ) agonist ) , unless surgical castration . N. Patients must recover acute toxicity relate prior therapy surgery . For chemotherapy , typically 3 4 week . O . Patients incontinent urine willing undergo bladder catheterization minimize risk radioactive contamination clothing , bed linen , patient 's environment . P. Concurrent treatment bisphosphonates allow . If bisphosphonates give within 2 week prior plan ( 153 ) SmEDTMP , 99Tc wholebody scintigraphy ( bone scan ) perform confirm uptake lesion . Bisphosphonates give within 48 hour ( 153 ) SmEDTMP administration . Q. Serum creatinine less equal 1.5 time upper limit normal OR creatinine clearance 24h urine collection great equal 60 mL/min . EXCLUSION CRITERIA : A . Patients evidence , list , immunocompromised : Human immunodeficiency virus ( HIV ) positivity due potential decrease tolerance risk severe side effect . Hepatitis B C positivity . Concurrent use topical steroid ( include steroid eye drop ) systemic steroid . This avoid immunosuppression may lead potential complication vaccinia ( prim vaccination ) . Nasal inhale steroid use permit . B . Patients autoimmune disease require treatment , Addison 's disease , Hashimoto 's thyroiditis , systemic lupus erythematosus , Sjogren 's syndrome , scleroderma , myasthenia gravis , Goodpasture 's syndrome , active Grave 's disease . Patients history autoimmunity require systemic immunosuppressive therapy threaten vital organ function , include central nervous system ( CNS ) , heart , lung , kidney , skin , gastrointestinal tract ( GI ) tract , allow . C. History allergy untoward reaction prior vaccination vaccinia virus component vaccinia vaccine regimen . Note : prior vaccination vaccinia require . D. Do administer recombinant vaccinia vaccine recipient , least 3 week vaccination , close household contact ( close household contact share housing close physical contact ) , person active history eczema eczematoid skin disorder ; acute , chronic exfoliative skin condition ( e.g. , atopic dermatitis , burn , impetigo , varicella zoster , severe acne , open rash wound ) condition resolve ; pregnant nursing woman ; child 3 year age ; immunodeficient immunosuppressed person ( disease therapy ) , include HIV infection . E. Serious intercurrent medical illness ( e.g. , one require treatment ) would interfere ability patient carry treatment program , include , limited , inflammatory bowel disease , Crohn 's disease , ulcerative colitis , active diverticulitis . F. Patients history cardiomyopathy symptomatic congestive heart failure ( unless stable treatment ) , symptomatic arrhythmia control medication . Unstable atherosclerotic heart disease ( e.g . unstable angina ) require active intervention history myocardial infarction embolic stroke within past 6 month . G. Patients cardiac disease fatigue , palpitation , dyspnea angina ordinary physical activity ( New York Heart Association class 2 great ) eligible . H. Patients history congestive heart failure objective evidence congestive heart failure physical exam image eligible , unless underlie cause treat patient document normal ejection fraction . I . Patients pulmonary disease fatigue dyspnea ordinary physical activity eligible . J. Concurrent chemotherapy . K. No brain metastasis history seizure , encephalitis , multiple sclerosis . L. Serious hypersensitivity reaction egg product . M. Prior splenectomy . N. Contraindicated patient know hypersensitivity EDTMP similar phosphonate compound . O . Patients symptomatic soft tissue disease parenchymal disease exclude . P. Radiation therapy bone within 4 week study entry . Q . Patients previously treat ( 153 ) SmEDTMP exclude . R. Patients require urgent local radiotherapy orthopedic stabilization .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Radionuclide</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Radiation</keyword>
	<keyword>PSA</keyword>
	<keyword>Hormone Refractory Prostate Cancer</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>